Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

VRCA Interest Expense

Cost of servicing the company's debt during the period.

Verrica Pharmaceuticals Inc.NASDAQ: VRCA

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of $160K fell 92.7% year over year, behind the -38.7% change in trailing-twelve-month interest expense. Sequentially, it fell 87.8% from the prior quarter. Over 3 fiscal years it compounded at +52.8% a year.

Context

  • Interest expense amounted to 21.8% of revenue in FY2025, down 102.6 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -92.7% toward the trailing-twelve-month pace of -38.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$160K-87.8% QoQ
Last fiscal yearDec 2025
$7.74M-17.7% YoY
LTMMar 2026
$5.7M-38.7% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-92.7%——
1 year-17.7%——
3-year CAGR+52.8%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
7.74M USD
Year-over-year change
-17.7%
4-year CAGR
+15.9%

Interest Expense vs competitors

How VRCA compares with its peers on the latest reported figures

  • VRCA's LTM Mar 2026 interest expense of $5.7M is the highest of the 5 companies compared; the peer median is $115.75K.
  • Its year-over-year change of -38.7% is the 2nd highest of 3, against a peer median of -37.3%.
  • Interest expense amounts to 15.3% of revenue for VRCA, versus a peer median of 1.9%.
VRCA Competitors Peer median
Interest Expense for VRCA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$5.7M -38.7%+52.8%15.3%
QTTBQ32 Bio Inc.LTM Mar 2026$1M -56.5%—1.9%
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$231.5K -18.1%-7.2%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ———
BOLDBoundless Bio, Inc.LTM Mar 2026$0 ———
Peer median (excluding VRCA) $115.75K-37.3%-7.2%1.9%

Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12M9.03M5.12M7.57M35.58M
Cost of Revenue472K725K746K2.74M3.44M
Gross Profit11.53M8.31M4.38M4.83M32.14M
Gross Margin96.1%92.0%85.4%63.8%90.3%
Research & Development15.93M12.2M20.3M11.84M8.86M
Selling, General & Admin26.98M17.41M47.31M58.82M35.22M
Operating Expenses42.44M29.6M70.14M70.75M44.08M
Depreciation & Amortization472K718K836K1.27M781K
EBITDA(30.31M)(21.6M)(62.2M)(65.9M)(9.36M)
EBITDA Margin-252.6%-239.1%-1213.8%-871.0%-26.3%
Operating Income(30.91M)(21.3M)(65.76M)(65.92M)(11.94M)
Operating Margin-257.6%-235.8%-1283.4%-871.3%-33.6%
Interest Income123K476K2.74M1.42M929K
Interest Expense4.3M2.17M3.96M9.41M7.74M
Other Income / Expenses(4.17M)(3.19M)(1.24M)(10.66M)(5.95M)
Income Before Tax(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Pre-Tax Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
Income Tax Expense00000
Net Income(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Net Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
EPS (Basic)(12.97)(7.17)(14.78)(14.78)(1.68)
EPS (Diluted)(12.97)(7.17)(14.78)(14.78)(1.68)
Weighted Avg Shares2.7M3.42M4.53M5.18M10.65M
Weighted Avg Shares (Diluted)2.7M3.42M4.53M5.18M10.65M

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Intrinsic Alpha fair value

Locked

Current Price

$3.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.